You are here

MAPCs Prevent GvHD

Graft-vs-host disease (GvHD) limits successful outcomes following allogeneic blood and marrow transplantation (allo-BMT). In a new STEM CELLS study, researchers led by Leland Metheny (UH Seidman Cancer Center, Cleveland, OH, USA) examined whether the administration of human, bone marrow-derived, multipotent adult progenitor cells (MAPC) could regulate experimental GvHD in vivo using established murine GvHD models. Overall, their findings provide valuable information regarding the biodistribution and regulatory capacity of MAPCs, which may inform future clinical trial design and support MAPC use.